WORLD HEALTH ORGANIZATION

The project combines BRICHOS protein effects with nerve growth factor (NGF) to study Alzheimer's pathology. Goals include testing BRICHOS-NGF transport efficiency, its function in mouse models, and potential application in patients. The research team is grateful for the grant enabling efficient project execution.

President-elect Trump praises polio vaccine, but lawyer Aaron Siri petitions FDA to revoke approval, citing safety concerns. Siri works closely with Trump's HHS pick, RFK Jr., who advocates for informed vaccine choice. FDA is reviewing the petition, and if confirmed, Kennedy could intervene in the review process. Polio vaccination is hailed as a global public health achievement, with no serious adverse events documented for the inactivated vaccine used in the US.

China's top drug regulator approved clinical trials of a Sinopharm-developed mpox vaccine, which has shown safety and effectiveness in preclinical research. Another Sinopharm subsidiary and the Institute of Microbiology are also researching mpox vaccines. The WHO declared mpox a global health emergency in August, with China reporting 46 infections in September and 38 in October.

Northern Gaza's neonatal care faces collapse due to Israel's evacuation order, affecting 20-25,000 people and the only NICU in the area. The order, citing safety from rocket attacks, forces vulnerable patients and healthcare workers into peril, amidst a healthcare system already in ruins.

Aaron Siri filed a petition to revoke the polio vaccine's federal approval, questioning its safety and efficacy. The vaccine, invented in 1955, eradicated polio in the U.S. and has prevented millions of cases globally. Siri seeks a double-blind trial and label changes, also targeting 13 other vaccines for aluminum content.

The cell free DNA (cfDNA) testing market is projected to grow from $7.07 billion in 2023 to $20.63 billion by 2028, driven by advances in liquid biopsy, personalized medicine, and cancer prevalence. Key trends include liquid biopsy adoption, NGS advancements, and AI integration.

WHO's 2024 guidance emphasizes diverse clinical trial participation, including ethnic minorities, LGBTQI+ populations, pregnant and lactating women, low-income patients, and those with language barriers. Dr. Jeremy Farrar highlights the need to benefit the broadest range of people, moving away from a one-size-fits-all approach. The guidance aims to improve evidence quality and healthcare access for underserved populations, potentially through cluster randomized trials in resource-limited settings.

FDA approved cosibelimab-ipdl for mCSCC or laCSCC patients unsuitable for curative surgery or radiation. Efficacy from Study CK-301-101 showed ORR of 47% for mCSCC and 48% for laCSCC. Common adverse reactions include fatigue, musculoskeletal pain, and rash. Recommended dose is 1,200 mg IV every three weeks.